Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting
Business Wire•11/11/2026•08:30 ET
1
Key Highlights
- ➤Tempus (TEM) will present six sarcoma research abstracts at the 2026 CTOS Annual Meeting
- ➤Three Tempus abstracts are scheduled for oral presentations in Seoul, November 18–21, 2026
- ➤Tempus’ de-identified multimodal library includes 45,085 patients across 615 rare cancer types
- ➤One study analyzes germline variant detection in sarcoma using 9,025 matched tumor/normal patients
Expert Statements
Ezra Cohen, Chief Medical Officer of Oncology at Tempus
“In rare diseases, such as sarcoma, small patient datasets make uncovering insights exceptionally challenging, which is where Tempus’ robust dataset brings critical value”
Ezra Cohen, Chief Medical Officer of Oncology at Tempus
“Importantly, Tempus is dedicated through its Orphan Disease Program to providing solutions to the inherent barriers in rare cancers, and to helping physicians develop and tailor therapies more precisely.”
Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting
Tempus AI, Inc. (NASDAQ: TEM) today announced that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 18–21 in Seoul. At this year’s meeting, Tempus will present clinical research on rare mesenchymal tumors, highlighting how advances in molecular diagnosis and classification are unlocking new treatment options.
Get started
Create a free account to read the full story.